Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Muscle Power After ACL Reconstruction: How Knee Extensor Strength Relates to Function

Official title: Muscle Function Following Anterior Cruciate Ligament Reconstruction: Impaired Power Output in Physically Active Individuals

Run by Centre Hospitalier Metropole Savoie · NCT07765173 · Data updated 2026-11-12

This study tests whether changes in knee extensor strength and power after ACL reconstruction are linked to how well patients function in daily life, up to 24 months post-surgery.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment110 (estimated)
SponsorCentre Hospitalier Metropole Savoie
Academic / other
Locations1 site (Challes-les-Eaux)
StatusRecruiting
StartedJune 8, 2026
Main results expectedJune 8, 2030
Study endsJune 8, 2030
Registry record updatedAugust 14, 2026
Trial IDNCT07765173 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Physically active individuals (Tegner ≥ 4) undergoing isolated or complex ACL reconstruction who have no prior ipsilateral knee surgery and can comply with study procedures.

Probably not a fit

Patients with recurrent ACL rupture, multi-ligament injuries, or comprehension difficulties may not benefit from the study outcomes.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial assesses objective knee extensor strength and power before ACL reconstruction and at 3, 6 months, with patient-reported function measured by IKDC-SKF. It uses force-velocity and power-velocity tests during cycling and knee extensions, plus isometric strength assessments. Correlations between physical measures and patient function will be analyzed to understand recovery patterns in physically active individuals. Participants include patients undergoing isolated or complex ACL reconstruction and will be followed for up to two years. The study is conducted at Medipôle de Savoie with support from Université Savoie Mont Blanc.

Why it matters

Potential benefit: If successful, the findings could help tailor rehabilitation to improve both objective knee function and patient-perceived outcomes after ACL reconstruction.

How similar studies have gone: Previous work in ACL rehabilitation has shown links between muscle function and functional outcomes, but this study adds detailed force-velocity profiling and longer follow-up in an active population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients requiring isolated or complex ACL reconstruction (combined with a meniscal injury)
* Patients who are physically active (Tegner score ≥ 4) and wish to resume such activity.
* Patients with no history of surgery on the ipsilateral knee (i.e., native knee).
* Patients able to comply with the study procedures
* Patients who have given their free and informed written consent, having been informed of the purpose of the study, its procedure and its risks.
* Be affiliated to a social security scheme.

Exclusion Criteria:

* Patient with comprehension difficulties
* Recurrent rupture of the ipsilateral ACL
* Multi-ligament injuries (i.e., injury to the medial collateral ligament, lateral collateral ligament or posterior cruciate ligament)

Where it's running

  • Médipôle de Savoie
    Challes-les-Eaux, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.